Browse SEMA3A

Summary
SymbolSEMA3A
Namesema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3A
Aliases SemD; coll-1; Hsema-I; sema III; SEMAD; COLL1; HH16; Hsema-III; SEMAIII; collapsin 1; semaphorin D; semaphor ......
Chromosomal Location7p12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted
Domain PF01403 Sema domain
Function

Involved in the development of the olfactory system and in neuronal control of puberty. Induces the collapse and paralysis of neuronal growth cones. Could serve as a ligand that guides specific growth cones by a motility-inhibiting mechanism. Binds to the complex neuropilin-1/plexin-1.

> Gene Ontology
 
Biological Process GO:0001558 regulation of cell growth
GO:0001667 ameboidal-type cell migration
GO:0001755 neural crest cell migration
GO:0001763 morphogenesis of a branching structure
GO:0001764 neuron migration
GO:0002027 regulation of heart rate
GO:0003002 regionalization
GO:0003013 circulatory system process
GO:0003015 heart process
GO:0006929 substrate-dependent cell migration
GO:0007350 blastoderm segmentation
GO:0007389 pattern specification process
GO:0007409 axonogenesis
GO:0007411 axon guidance
GO:0007413 axonal fasciculation
GO:0007431 salivary gland development
GO:0007435 salivary gland morphogenesis
GO:0007548 sex differentiation
GO:0008015 blood circulation
GO:0008016 regulation of heart contraction
GO:0008037 cell recognition
GO:0008038 neuron recognition
GO:0008045 motor neuron axon guidance
GO:0008361 regulation of cell size
GO:0008406 gonad development
GO:0008584 male gonad development
GO:0009880 embryonic pattern specification
GO:0010631 epithelial cell migration
GO:0010632 regulation of epithelial cell migration
GO:0010633 negative regulation of epithelial cell migration
GO:0010720 positive regulation of cell development
GO:0010721 negative regulation of cell development
GO:0010769 regulation of cell morphogenesis involved in differentiation
GO:0010771 negative regulation of cell morphogenesis involved in differentiation
GO:0010975 regulation of neuron projection development
GO:0010977 negative regulation of neuron projection development
GO:0014031 mesenchymal cell development
GO:0014032 neural crest cell development
GO:0014033 neural crest cell differentiation
GO:0016049 cell growth
GO:0016358 dendrite development
GO:0021536 diencephalon development
GO:0021537 telencephalon development
GO:0021543 pallium development
GO:0021545 cranial nerve development
GO:0021559 trigeminal nerve development
GO:0021561 facial nerve development
GO:0021602 cranial nerve morphogenesis
GO:0021604 cranial nerve structural organization
GO:0021610 facial nerve morphogenesis
GO:0021612 facial nerve structural organization
GO:0021636 trigeminal nerve morphogenesis
GO:0021637 trigeminal nerve structural organization
GO:0021675 nerve development
GO:0021761 limbic system development
GO:0021772 olfactory bulb development
GO:0021783 preganglionic parasympathetic fiber development
GO:0021785 branchiomotor neuron axon guidance
GO:0021795 cerebral cortex cell migration
GO:0021800 cerebral cortex tangential migration
GO:0021824 cerebral cortex tangential migration using cell-axon interactions
GO:0021825 substrate-dependent cerebral cortex tangential migration
GO:0021828 gonadotrophin-releasing hormone neuronal migration to the hypothalamus
GO:0021854 hypothalamus development
GO:0021855 hypothalamus cell migration
GO:0021856 hypothalamic tangential migration using cell-axon interactions
GO:0021872 forebrain generation of neurons
GO:0021879 forebrain neuron differentiation
GO:0021884 forebrain neuron development
GO:0021885 forebrain cell migration
GO:0021886 hypothalamus gonadotrophin-releasing hormone neuron differentiation
GO:0021888 hypothalamus gonadotrophin-releasing hormone neuron development
GO:0021953 central nervous system neuron differentiation
GO:0021954 central nervous system neuron development
GO:0021979 hypothalamus cell differentiation
GO:0021987 cerebral cortex development
GO:0021988 olfactory lobe development
GO:0022029 telencephalon cell migration
GO:0022604 regulation of cell morphogenesis
GO:0022612 gland morphogenesis
GO:0030308 negative regulation of cell growth
GO:0030335 positive regulation of cell migration
GO:0030336 negative regulation of cell migration
GO:0030516 regulation of axon extension
GO:0030517 negative regulation of axon extension
GO:0030900 forebrain development
GO:0031345 negative regulation of cell projection organization
GO:0032102 negative regulation of response to external stimulus
GO:0032535 regulation of cellular component size
GO:0035272 exocrine system development
GO:0035282 segmentation
GO:0035290 trunk segmentation
GO:0036484 trunk neural crest cell migration
GO:0036486 ventral trunk neural crest cell migration
GO:0040013 negative regulation of locomotion
GO:0040017 positive regulation of locomotion
GO:0044057 regulation of system process
GO:0045137 development of primary sexual characteristics
GO:0045665 negative regulation of neuron differentiation
GO:0045926 negative regulation of growth
GO:0046546 development of primary male sexual characteristics
GO:0046661 male sex differentiation
GO:0048483 autonomic nervous system development
GO:0048485 sympathetic nervous system development
GO:0048486 parasympathetic nervous system development
GO:0048532 anatomical structure arrangement
GO:0048588 developmental cell growth
GO:0048608 reproductive structure development
GO:0048638 regulation of developmental growth
GO:0048640 negative regulation of developmental growth
GO:0048667 cell morphogenesis involved in neuron differentiation
GO:0048675 axon extension
GO:0048732 gland development
GO:0048762 mesenchymal cell differentiation
GO:0048813 dendrite morphogenesis
GO:0048841 regulation of axon extension involved in axon guidance
GO:0048843 negative regulation of axon extension involved in axon guidance
GO:0048846 axon extension involved in axon guidance
GO:0048863 stem cell differentiation
GO:0048864 stem cell development
GO:0048880 sensory system development
GO:0050768 negative regulation of neurogenesis
GO:0050769 positive regulation of neurogenesis
GO:0050770 regulation of axonogenesis
GO:0050771 negative regulation of axonogenesis
GO:0050919 negative chemotaxis
GO:0050920 regulation of chemotaxis
GO:0050922 negative regulation of chemotaxis
GO:0051271 negative regulation of cellular component movement
GO:0051272 positive regulation of cellular component movement
GO:0051961 negative regulation of nervous system development
GO:0051962 positive regulation of nervous system development
GO:0060047 heart contraction
GO:0060384 innervation
GO:0060385 axonogenesis involved in innervation
GO:0060445 branching involved in salivary gland morphogenesis
GO:0060485 mesenchyme development
GO:0060560 developmental growth involved in morphogenesis
GO:0060600 dichotomous subdivision of an epithelial terminal unit
GO:0060666 dichotomous subdivision of terminal units involved in salivary gland branching
GO:0061138 morphogenesis of a branching epithelium
GO:0061387 regulation of extent of cell growth
GO:0061458 reproductive system development
GO:0061548 ganglion development
GO:0061549 sympathetic ganglion development
GO:0061550 cranial ganglion development
GO:0061551 trigeminal ganglion development
GO:0061564 axon development
GO:0071526 semaphorin-plexin signaling pathway
GO:0090066 regulation of anatomical structure size
GO:0090130 tissue migration
GO:0090132 epithelium migration
GO:0097485 neuron projection guidance
GO:0097490 sympathetic neuron projection extension
GO:0097491 sympathetic neuron projection guidance
GO:1901166 neural crest cell migration involved in autonomic nervous system development
GO:1902284 neuron projection extension involved in neuron projection guidance
GO:1902285 semaphorin-plexin signaling pathway involved in neuron projection guidance
GO:1902287 semaphorin-plexin signaling pathway involved in axon guidance
GO:1902667 regulation of axon guidance
GO:1902668 negative regulation of axon guidance
GO:1903045 neural crest cell migration involved in sympathetic nervous system development
GO:1903375 facioacoustic ganglion development
GO:1903522 regulation of blood circulation
GO:1990138 neuron projection extension
GO:2000018 regulation of male gonad development
GO:2000020 positive regulation of male gonad development
GO:2000146 negative regulation of cell motility
GO:2000147 positive regulation of cell motility
GO:2000241 regulation of reproductive process
GO:2000243 positive regulation of reproductive process
GO:2001222 regulation of neuron migration
GO:2001224 positive regulation of neuron migration
Molecular Function GO:0030215 semaphorin receptor binding
GO:0038191 neuropilin binding
GO:0045499 chemorepellent activity
Cellular Component GO:0030424 axon
GO:0030425 dendrite
> KEGG and Reactome Pathway
 
KEGG hsa04360 Axon guidance
Reactome R-HSA-422475: Axon guidance
R-HSA-399956: CRMPs in Sema3A signaling
R-HSA-1266738: Developmental Biology
R-HSA-399955: SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
R-HSA-399954: Sema3A PAK dependent Axon repulsion
R-HSA-373755: Semaphorin interactions
Summary
SymbolSEMA3A
Namesema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3A
Aliases SemD; coll-1; Hsema-I; sema III; SEMAD; COLL1; HH16; Hsema-III; SEMAIII; collapsin 1; semaphorin D; semaphor ......
Chromosomal Location7p12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SEMA3A and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between SEMA3A and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
27197153Breast CarcinomaPromote immunity (T cell function)In human breast cancer specimens, we found that immunohistochemical levels of SEMA3A correlated with the expression of genes characteristic of M1 macrophages, CD8(+) T cells, and NK cells, while inversely correlating with established characters of malignancy.
Summary
SymbolSEMA3A
Namesema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3A
Aliases SemD; coll-1; Hsema-I; sema III; SEMAD; COLL1; HH16; Hsema-III; SEMAIII; collapsin 1; semaphorin D; semaphor ......
Chromosomal Location7p12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SEMA3A in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSEMA3A
Namesema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3A
Aliases SemD; coll-1; Hsema-I; sema III; SEMAD; COLL1; HH16; Hsema-III; SEMAIII; collapsin 1; semaphorin D; semaphor ......
Chromosomal Location7p12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SEMA3A in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-1.330.0976
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.7930.193
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.9960.4
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.6250.2
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.850.557
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.3460.836
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2340.753
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-1.940.112
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11122.690.0332
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.330.734
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.2790.826
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.3030.136
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SEMA3A in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.74.1-0.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.75.1-1.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.509.50.492
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.118.8-7.71
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 472528.6-3.61
1329033130MelanomaallAnti-PD-1 (nivolumab) 38277.907.90.26
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSEMA3A
Namesema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3A
Aliases SemD; coll-1; Hsema-I; sema III; SEMAD; COLL1; HH16; Hsema-III; SEMAIII; collapsin 1; semaphorin D; semaphor ......
Chromosomal Location7p12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SEMA3A. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSEMA3A
Namesema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3A
Aliases SemD; coll-1; Hsema-I; sema III; SEMAD; COLL1; HH16; Hsema-III; SEMAIII; collapsin 1; semaphorin D; semaphor ......
Chromosomal Location7p12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SEMA3A. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SEMA3A.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSEMA3A
Namesema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3A
Aliases SemD; coll-1; Hsema-I; sema III; SEMAD; COLL1; HH16; Hsema-III; SEMAIII; collapsin 1; semaphorin D; semaphor ......
Chromosomal Location7p12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SEMA3A. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSEMA3A
Namesema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3A
Aliases SemD; coll-1; Hsema-I; sema III; SEMAD; COLL1; HH16; Hsema-III; SEMAIII; collapsin 1; semaphorin D; semaphor ......
Chromosomal Location7p12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SEMA3A expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSEMA3A
Namesema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3A
Aliases SemD; coll-1; Hsema-I; sema III; SEMAD; COLL1; HH16; Hsema-III; SEMAIII; collapsin 1; semaphorin D; semaphor ......
Chromosomal Location7p12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SEMA3A and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSEMA3A
Namesema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3A
Aliases SemD; coll-1; Hsema-I; sema III; SEMAD; COLL1; HH16; Hsema-III; SEMAIII; collapsin 1; semaphorin D; semaphor ......
Chromosomal Location7p12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SEMA3A collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.